Acyclovir Dosing for Herpes Zoster in CKD on Thrice Weekly Hemodialysis
For a patient with chronic kidney disease on thrice-weekly hemodialysis with herpes zoster, administer acyclovir 200 mg orally every 12 hours, with the first daily dose given after each dialysis session 1, 2.
Rationale for This Dosing Regimen
The guideline-based dosing for hemodialysis patients differs substantially from standard herpes zoster treatment due to critical pharmacokinetic alterations:
- Standard herpes zoster dose: 800 mg orally 5 times daily for 7-10 days 2
- Hemodialysis-adjusted dose: 200 mg every 12 hours, administered after dialysis 1
This dramatic dose reduction is necessary because acyclovir is primarily renally excreted, and patients with end-stage renal disease have a plasma half-life of approximately 20 hours (versus 2-3 hours in normal renal function) 3, 4. Hemodialysis removes approximately 51-61% of circulating acyclovir over a 3-6 hour session 3, 4, 5.
Critical Timing Considerations
Administer acyclovir immediately after each hemodialysis session to:
- Facilitate directly observed therapy (thrice weekly dosing aligns with dialysis schedule)
- Prevent premature drug removal by dialysis 1, 6
- Maintain therapeutic plasma levels between dialysis sessions
On non-dialysis days, continue the 200 mg every 12 hours schedule.
Alternative Antiviral Options
If oral acyclovir is insufficient or the patient has disseminated/severe disease:
Valacyclovir: 500 mg after each dialysis session 1, 7
- Better bioavailability than acyclovir but same renal clearance concerns
Famciclovir: 125 mg after each dialysis session 1
- Alternative with similar efficacy profile
Intravenous acyclovir: Reserved for disseminated or invasive herpes zoster 8
- Requires even more aggressive dose reduction
- Should be accompanied by temporary reduction in immunosuppression if patient is a transplant recipient 8
Neurotoxicity Risk and Monitoring
The most critical complication in dialysis patients is acyclovir-induced neurotoxicity, which can occur even with "appropriately adjusted" doses 9, 3, 10, 11. This occurs because:
- The metabolite CMMG (9-carboxymethoxymethylguanine) accumulates in renal failure
- Neurotoxicity manifests as confusion, hallucinations, agitation, delirium, myoclonus, and seizures 9, 10, 5
- Symptoms typically appear 2-4 days after treatment initiation 10, 11
Monitor closely for:
- Mental status changes
- Visual or auditory hallucinations
- Ataxia or gait disturbances
- Involuntary movements
If neurotoxicity develops, immediately discontinue acyclovir and perform emergent hemodialysis 10, 5. Symptoms typically resolve after 2-3 consecutive hemodialysis sessions 10.
Common Pitfalls to Avoid
Do not use the manufacturer's standard renal dosing adjustment (800 mg every 12 hours for CrCl 0-10 mL/min) 2 - this is still too high for dialysis patients and increases neurotoxicity risk 9, 3
Do not give acyclovir before dialysis - this wastes the dose as dialysis will remove it 1, 6
Do not assume the FDA label dosing is safe - multiple case reports demonstrate neurotoxicity even with "recommended" doses in dialysis patients 9, 10, 11
Avoid intravenous acyclovir unless absolutely necessary - it carries the highest AKI risk among antivirals 12 and requires even more careful dosing
Treatment Duration
Continue treatment until all lesions have scabbed 8, typically 7-10 days. The KDIGO guidelines for kidney transplant recipients recommend this endpoint for both uncomplicated and complicated herpes zoster 8, which is reasonable to extrapolate to dialysis patients.
Special Considerations
Adequate hydration should be maintained to minimize crystalluria risk, though this is less of a concern with oral versus intravenous administration 2.
Consider serum acyclovir level monitoring if available, particularly if any neurological symptoms develop. Therapeutic levels are 0.12-10.8 mg/L; levels above this range increase neurotoxicity risk 10.